BIOMEMORY LAUNCHES DNA SHIELD, THE FIRST COMMERCIAL PRODUCT BUILT ON ITS MOLECULAR IT PLATFORM
Following the acquisition of Catalog's assets and the appointment of Laurent Guengant as CEO earlier this year, Biomemory opened Early Access to DNA shield, its first commercial product for sovereign data protection, establishing the company as an early leader in molecular IT. PARIS and...
Covered in this story
What has happened since
- Ginkgo Bioworks Holdings Inc Class is down 13.9% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ginkgo Bioworks Holdings Inc Class →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.